Qiagen (NYSE:QGEN) Cut to “Neutral” at Robert W. Baird

Robert W. Baird cut shares of Qiagen (NYSE:QGEN) from an outperform rating to a neutral rating in a report issued on Wednesday, MarketBeat Ratings reports. Robert W. Baird currently has $42.00 price target on the stock, down from their prior price target of $52.00.

Several other equities analysts also recently issued reports on the stock. UBS Group decreased their price objective on shares of Qiagen from $50.00 to $48.00 and set a “neutral” rating for the company in a research note on Friday, February 7th. Morgan Stanley reissued an “equal weight” rating and issued a $46.67 target price (down from $48.61) on shares of Qiagen in a research report on Monday, January 6th. Finally, Jefferies Financial Group restated a “buy” rating and set a $52.50 price target (up previously from $40.83) on shares of Qiagen in a research note on Tuesday, December 10th. Seven analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $47.71.

Qiagen Trading Up 2.5 %

QGEN opened at $39.52 on Wednesday. The business’s 50-day simple moving average is $43.05 and its 200-day simple moving average is $43.04. The company has a market cap of $8.77 billion, a P/E ratio of 110.03, a PEG ratio of 2.43 and a beta of 0.36. Qiagen has a one year low of $38.49 and a one year high of $49.30. The company has a debt-to-equity ratio of 0.38, a quick ratio of 3.09 and a current ratio of 3.61.

Qiagen (NYSE:QGEN) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $0.61 EPS for the quarter, beating the consensus estimate of $0.60 by $0.01. Qiagen had a net margin of 4.23% and a return on equity of 13.92%. As a group, equities research analysts expect that Qiagen will post 2.26 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Brown Brothers Harriman & Co. acquired a new stake in shares of Qiagen during the fourth quarter worth $37,000. Geneos Wealth Management Inc. lifted its stake in shares of Qiagen by 41.5% in the 4th quarter. Geneos Wealth Management Inc. now owns 856 shares of the company’s stock worth $38,000 after acquiring an additional 251 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in shares of Qiagen by 152.5% in the fourth quarter. EverSource Wealth Advisors LLC now owns 871 shares of the company’s stock valued at $39,000 after acquiring an additional 526 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new position in shares of Qiagen during the third quarter worth about $53,000. Finally, Smartleaf Asset Management LLC increased its stake in shares of Qiagen by 148.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,399 shares of the company’s stock worth $63,000 after acquiring an additional 835 shares during the period. 70.00% of the stock is currently owned by hedge funds and other institutional investors.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.